The renal glomerulus works as a size filter: it easily lets small molecules through and holds back large ones, such as albumin. Most therapeutic and research peptides are below that threshold, so they are filtered each time blood passes through the kidney and then broken down in the tubules.
That is why size and half-life are so closely linked. Every strategy to extend a peptide's action aims, in part, to take it out of the filter's reach: binding it to albumin (lipidation, DAC), making it bigger (PEGylation, fusion to antibody fragments) or forming slow-release depots.
Kidney function in the study model also matters: in animals or populations with reduced kidney function, exposure to a renally cleared peptide may be higher.
If a peptide is eliminated within minutes, there are almost always two combined culprits: proteases and the kidney. Knowing which one dominates guides the design strategy.
Related terms
Learn it in depth at the Peptide University
- Pharmacokinetics: ADME and parameters · Module 2
- Half-life engineering · Module 2
- Non-injectable routes: intranasal, oral and topical · Module 8
- Precautions, interactions and monitoring · Module 10
Definition for educational and scientific purposes. It is not medical advice or a recommendation for use. NeoPeptidos products are sold labelled for research use only (RUO).